These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 8591985

  • 21. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.
    Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H.
    Oncogene; 1993 Sep; 8(9):2425-32. PubMed ID: 8395680
    [Abstract] [Full Text] [Related]

  • 22. Effects of cyclic AMP on components of the cell cycle machinery regulating DNA synthesis in cultured astrocytes.
    Gagelin C, Toru-Delbauffe D, Gavaret JM, Pierre M.
    J Neurochem; 1999 Nov; 73(5):1799-805. PubMed ID: 10537037
    [Abstract] [Full Text] [Related]

  • 23. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty.
    Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andrés V.
    Circ Res; 1997 Mar; 80(3):418-26. PubMed ID: 9048663
    [Abstract] [Full Text] [Related]

  • 24. Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine.
    Yuan ZM, Huang Y, Kraeft SK, Chen LB, Kharbanda S, Kufe D.
    Oncogene; 1996 Sep 05; 13(5):939-46. PubMed ID: 8806683
    [Abstract] [Full Text] [Related]

  • 25. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells.
    Hu B, Mitra J, van den Heuvel S, Enders GH.
    Mol Cell Biol; 2001 Apr 05; 21(8):2755-66. PubMed ID: 11283255
    [Abstract] [Full Text] [Related]

  • 26. A variant form of cyclin-dependent kinase 2 (Cdk2) in a malignantly transformed rat thyroid (FRTL-Tc) cell line.
    Kotani S, Endo T, Kitagawa M, Higashi H, Onaya T.
    Oncogene; 1995 Feb 16; 10(4):663-9. PubMed ID: 7862443
    [Abstract] [Full Text] [Related]

  • 27. Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs.
    Rhodes N, Innes CL, Propst F, Paules RS.
    Oncogene; 1997 Jun 26; 14(25):3017-27. PubMed ID: 9223665
    [Abstract] [Full Text] [Related]

  • 28. The cdk2 kinase is required for the G1-to-S transition in mammalian cells.
    Tsai LH, Lees E, Faha B, Harlow E, Riabowol K.
    Oncogene; 1993 Jun 26; 8(6):1593-602. PubMed ID: 8502482
    [Abstract] [Full Text] [Related]

  • 29. cAMP-dependent reorganization of the Cajal bodies and splicing machinery in cultured Schwann cells.
    Fernandez R, Pena E, Navascues J, Casafont I, Lafarga M, Berciano MT.
    Glia; 2002 Dec 26; 40(3):378-88. PubMed ID: 12420317
    [Abstract] [Full Text] [Related]

  • 30. p53-independent increase in p21WAF1 and reciprocal down-regulation of cyclin A and proliferating cell nuclear antigen in bromodeoxyuridine-mediated growth arrest of human melanoma cells.
    Strasberg Rieber M, Welch DR, Miele ME, Rieber M.
    Cell Growth Differ; 1996 Feb 26; 7(2):197-202. PubMed ID: 8822203
    [Abstract] [Full Text] [Related]

  • 31. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently.
    O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, Longo DL, Kohn KW.
    J Biol Chem; 1993 Apr 15; 268(11):8298-308. PubMed ID: 8463339
    [Abstract] [Full Text] [Related]

  • 32. Dynamics of the cell cycle engine: Cdk2-kinase and the transition into mitosis.
    Kaern M, Hunding A.
    J Theor Biol; 1998 Jul 07; 193(1):47-57. PubMed ID: 9689942
    [Abstract] [Full Text] [Related]

  • 33. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.
    Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S.
    Hepatology; 2001 Feb 07; 33(2):346-56. PubMed ID: 11172336
    [Abstract] [Full Text] [Related]

  • 34. Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR.
    Goldstone S, Pavey S, Forrest A, Sinnamon J, Gabrielli B.
    Oncogene; 2001 Feb 22; 20(8):921-32. PubMed ID: 11314027
    [Abstract] [Full Text] [Related]

  • 35. Stabilization of cyclin E and cdk2 mRNAs at G1/S transition in Rat-1A cells emerging from the G0 state.
    Oda S, Nishida J, Nakabeppu Y, Sekiguchi M.
    Oncogene; 1995 Apr 06; 10(7):1343-51. PubMed ID: 7731685
    [Abstract] [Full Text] [Related]

  • 36. Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells.
    Van Dolah FM, Ramsdell JS.
    J Cell Physiol; 1996 Jan 06; 166(1):49-56. PubMed ID: 8557775
    [Abstract] [Full Text] [Related]

  • 37. Differential cyclin-dependent kinase expression and activation in human colon cancer.
    Salh B, Bergman D, Marotta A, Pelech SL.
    Anticancer Res; 1999 Jan 06; 19(1B):741-8. PubMed ID: 10216486
    [Abstract] [Full Text] [Related]

  • 38. [The characterization of human cdc2 kinase and CDK2].
    Yasuda H, Kamijo M, Ohba Y.
    Yakugaku Zasshi; 1993 Dec 06; 113(12):829-46. PubMed ID: 8301538
    [Abstract] [Full Text] [Related]

  • 39. Fos proteins can act as negative regulators of cell growth independently of the fos transforming pathway.
    Balsalobre A, Jolicoeur P.
    Oncogene; 1995 Aug 03; 11(3):455-65. PubMed ID: 7630629
    [Abstract] [Full Text] [Related]

  • 40. Microsomal localization of cyclin A and cdk2 in proliferating rat liver cells.
    Castro A, Jaumot M, Vergés M, Agell N, Bachs O.
    Biochem Biophys Res Commun; 1994 Jun 30; 201(3):1072-8. PubMed ID: 8024548
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.